Avita Strengthens Board

Avita Strengthens Board 
10/22/12 --  Regenerative medicine company Avita Medical Ltd. (ASX:
AVH), (OTCQX: AVMXY) announced that further to Australian Stock
Exchange announcements on 5 September 2012 and 16 October 2012 and
following today's Shareholder Meeting it is pleased to announce the
appointments of Jeremy Curnock Cook and Matt McNamara to the board of
Avita Medical. The strengthening of Avita's board follows the
company's successful capital raising of A$10.3m.  
Avita Medical's Chairman, Dalton Gooding stated the appointments of
Mr Curnock Cook and Mr McNamara further strengthen Avita's board.  
"I am delighted that both Jeremy and Matt have been appointed as
directors of Avita Medical and I extend a warm welcome on behalf of
the board," Mr Gooding said.  
"We look forward to drawing on the extensive experience that both
Jeremy and Matt have in biotechnology and healthcare as we continue
to increase our ReCell(R) Spray-On Skin(R) sales."  
Mr Curnock Cook is currently on a number of boards of international
healthcare and biotechnology companies. Jeremy is the former head of
the life science private equity team at Rothschild Asset Management,
was responsible for the launch of the first dedicated biotechnology
fund for the Australian market and the launch of a joint venture with
Johnson & Johnson Development Corporation for the creation of
Healthcare Ventures, an investment vehicle dedicated to seed stage
investments in Europe, as well as the conception and launch of the
International Biotechnology Trust (IBT).  
Mr McNamara is currently the Chief Investment Officer and Fund
Manager of Octa Phillip Bioscience Managers. Matt has over 23 years
experience in the healthcare & medical sciences sector. After
initially being a molecular biology research assistant, Matt spent 11
years in Sales & Marketing and General Management with Merck & Co.
and Johnson & Johnson Medical Pty. Ltd. respectively. He has served
as SVP Business Development for a University of Sydney spin out,
eBioinformatics Inc., and was CEO of a Life Sciences Venture Capital
fund, SciCapital Pty. Ltd.  
The board would also like to thank Dr Paul Watt who has retired from
the board of Avita Medical effective immediately. The board would
like to acknowledge Dr Watt's extensive contribution that he has made
over a 10 year period including 6 years as a director of pre-merger
company Visiomed Limited. Dalton Gooding stated, "The board wishes Dr
Watt all the very best and success with his future endeavors." 
 Avita Medical (http://www.avitamedical.com/)
develops and distributes regenerative and tissue-engineered products
for the treatment of a broad range of wounds, scars and skin defects.
Avita's patented and proprietary tissue-culture, collection and
application technology provides innovative treatment solutions
derived from a patient's own skin. The company's lead product,
ReCell(R) Spray-On Skin(TM), is used in a wide variety of burns,
plastic, reconstructive and cosmetic procedures. ReCell is patented,
CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared
in China. ReCell is on market and generating early revenues. ReCell
is not available for sale in the United States; in the U.S. ReCell is
an investigational device limited by federal law to investigational
use. A Phase III FDA trial is in process. 
Avita Medical Ltd. 
Stella Sung, Ph.D. 
Business Development Officer 
Phone:+1 818-356-9400
Email: ssung@avitamedical.com 
Investor Relations: 
ProActive Capital 
Jeff Ramson 
+1 646-863-6893
Press spacebar to pause and continue. Press esc to stop.